Register Login

ALLARITY THERAPEUTICS, INC. (ALLR)

(90% Positive) ALLARITY THERAPEUTICS, INC. (ALLR) Announces Enrollment Update for Association Due to Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot April 22, 2026, 12:16 p.m.

    📋 ALLARITY THERAPEUTICS, INC. (ALLR) - Clinical Trial Update

    Filing Date: 2026-04-22

    Accepted: 2026-04-22 08:15:32

    Event Type: Clinical Trial Update

    Event Details:

    ALLARITY THERAPEUTICS, INC. (ALLR) Announces Clinical Trial Update ALLARITY THERAPEUTICS, INC. (ALLR) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: Association, survival
    • Clinical Stage: phase 2 trial, phase 2
    • Collaboration: Drug Response Predictor

    🔬 Clinical Development Pipeline (ALLARITY THERAPEUTICS, INC.):

    Product Type Development Stage Therapeutic Area Source
    Drug Response Predictor® (DRP) DEVICE Preclinical Ovarian Cancer ClinicalTrials.gov
    2X-121 and dovitinib DRUG Phase PHASE1 Advanced Solid Tumors ClinicalTrials.gov
    Ixabepilone Injection DRUG Phase PHASE2 Metastatic Breast Cancer ClinicalTrials.gov
    2X-121 DRUG Phase PHASE2 Advanced Ovarian Cancer ClinicalTrials.gov
    Irofulven DRUG Phase PHASE2 Metastatic Castration-Resistant Prostate Cancer Patients ClinicalTrials.gov
    PARP inhibitor 2X-121 DRUG Phase PHASE2 Metastatic Breast Cancer ClinicalTrials.gov
    APO010 DRUG Phase PHASE1 Relapsed/Refractory Multiple Myeloma ClinicalTrials.gov
    LiPlaCis DRUG Phase PHASE1 Phase 1: Advanced or Refractory Solid Tumours ClinicalTrials.gov

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: ALLARITY THERAPEUTICS, INC.
    • Ticker Symbol: ALLR

Search

News categories